Literature DB >> 6603261

Serial immune testing in surgically resected lung cancer patients.

D P Braun, S Nisius, A Hollinshead, J E Harris.   

Abstract

Immunoregulation of phytohemagglutinin (PHA) responsiveness by glass-adherent cells and prostaglandin-synthesizing cells was serially monitored in the peripheral blood mononuclear cells (PBMC) of surgically resected stage I and stage II lung cancer patients entered on a trial of adjuvant immunotherapy. The relationship between immunoregulatory cell function, immunocompetence, and disease relapse was determined. Immunoregulatory activity was measured in PHA-stimulated cultures in the presence and absence of 2 micrograms/ml indomethacin and in the presence and absence of glass-adherent cells. In each instance of disease relapse seen, an increase in immunoregulatory cell function to a level significantly different from normal was observed 3 months prior to or coincident with clinical confirmation of disease recurrence. This was usually associated with a decline in PHA responsiveness. In the patients who did not relapse, the levels of PHA responsiveness and immunoregulatory function persisted within normal limits throughout the course of study. Percentages and numbers of leukocytes and leukocyte subsets and delayed cutaneous hypersensitivity were also monitored in this study, but could not be consistently correlated with early changes in clinical disease status. These data suggest that the development of indomethacin-sensitive and glass-adherent suppressor cells may precede and predict for tumor recurrence in surgically resected lung cancer patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6603261     DOI: 10.1007/bf00199701

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  24 in total

Review 1.  In vitro tests of cellular immunity in man.

Authors:  R B Herberman
Journal:  Invest Cell Pathol       Date:  1978 Jul-Sep

2.  Immunologic testing as a guide to cancer management.

Authors:  H J Wanebo
Journal:  Surg Clin North Am       Date:  1979-04       Impact factor: 2.741

3.  Chemoimmunotherapy increases the lymphocyte reactivity of melanoma patients.

Authors:  J Berkelhammer; M J Mastrangelo; R E Bellet; D Berd; R T Prehn
Journal:  Eur J Cancer       Date:  1979-02       Impact factor: 9.162

4.  Multiple concurrent immunoregulatory defects in cancer patients with depressed PHA-induced lymphocyte DNA synthesis.

Authors:  D P Braun; M A Cobleigh; J E Harris
Journal:  Clin Immunol Immunopathol       Date:  1980-09

Review 5.  Immunobiologic aspects of the brain and human gliomas. A review.

Authors:  C J Wikstrand; D D Bigner
Journal:  Am J Pathol       Date:  1980-02       Impact factor: 4.307

6.  Failure of lymphocyte microcytotoxicity to distinguish relapsers from non-relapsers in melanoma patients receiving post-surgical adjuvant chemotherapy.

Authors:  J Berkelhammer; M J Mastrangelo; R E Bellet; R T Prehn; L H Thibault
Journal:  Eur J Cancer       Date:  1978-07       Impact factor: 9.162

7.  Assessment of cellular immune response to cancer of the breast.

Authors:  R B Herberman
Journal:  Ann Clin Lab Sci       Date:  1979 Nov-Dec       Impact factor: 1.256

8.  Immunological monitoring and immunotherapy in carcinoma of the lung.

Authors:  J L Weese; R B Herberman; E Perlin; M Mills; W Heims; J Blom; D Green; J Reid; S Bellinger; I Law; J L McCoy; J H Dean; G B Cannon; J Djeu
Journal:  Int J Cancer       Date:  1976-12-15       Impact factor: 7.396

9.  Prostaglandin suppression of mitogen-stimulated lymphocytes in vitro. Changes with mitogen dose and preincubation.

Authors:  J S Goodwin; R P Messner; G T Peake
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

10.  Horizontal studies of cell mediated immune reactions to autologous tumour antigens in patients with operable mammary carcinoma.

Authors:  B M Jones; A R Turnbull
Journal:  Br J Cancer       Date:  1975-09       Impact factor: 7.640

View more
  4 in total

Review 1.  Serial immune function testing to predict clinical disease relapse in patients with solid tumors.

Authors:  D P Braun; J E Harris
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

2.  Serial immunological testing in patients with gastric cancer.

Authors:  M Zembala; T Popiela; D Kowalczyk; B Mytar; A Pituch-Noworolska; I Ruggiero; W Uracz; A Czupryna; H Labza
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

3.  Indomethacin-induced augmentation of lymphoproliferative responses in patients with head and neck cancer.

Authors:  K J McCormick; W R Panje
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

4.  Immune reactivity in cattle with ocular squamous cell carcinoma after intralesional BCG immunotherapy.

Authors:  W R Klein; P A Steerenberg; F Poelma; E vd Wiel; V P Rutten; W Misdorp; W H de Jong; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.